193 related articles for article (PubMed ID: 37500798)
21. Secretion of hepatocyte growth factor and vascular endothelial growth factor during uveal melanoma-monocyte in vitro interactions.
Cools-Lartigue J; Marshall JC; Caissie AL; Saraiva VS; Burnier MN
Melanoma Res; 2005 Jun; 15(3):141-5. PubMed ID: 15917694
[TBL] [Abstract][Full Text] [Related]
22. Insulin-like growth factor-1 as a predictive biomarker for metastatic uveal melanoma in humans.
Frenkel S; Zloto O; Pe'er J; Barak V
Invest Ophthalmol Vis Sci; 2013 Jan; 54(1):490-3. PubMed ID: 23197685
[TBL] [Abstract][Full Text] [Related]
23. Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model.
Surriga O; Rajasekhar VK; Ambrosini G; Dogan Y; Huang R; Schwartz GK
Mol Cancer Ther; 2013 Dec; 12(12):2817-26. PubMed ID: 24140933
[TBL] [Abstract][Full Text] [Related]
24. Uveal melanoma and macular degeneration: molecular biology and potential therapeutic applications.
Economou MA
Acta Ophthalmol; 2008 Dec; 86(8):930-1. PubMed ID: 19086934
[TBL] [Abstract][Full Text] [Related]
25. Verification of EZH2 as a druggable target in metastatic uveal melanoma.
Jin B; Zhang P; Zou H; Ye H; Wang Y; Zhang J; Yang H; Pan J
Mol Cancer; 2020 Mar; 19(1):52. PubMed ID: 32127003
[TBL] [Abstract][Full Text] [Related]
26. Targeting primary and metastatic uveal melanoma with a G protein inhibitor.
Onken MD; Makepeace CM; Kaltenbronn KM; Choi J; Hernandez-Aya L; Weilbaecher KN; Piggott KD; Rao PK; Yuede CM; Dixon AJ; Osei-Owusu P; Cooper JA; Blumer KJ
J Biol Chem; 2021; 296():100403. PubMed ID: 33577798
[TBL] [Abstract][Full Text] [Related]
27. Arylsulfonamide 64B Inhibits Hypoxia/HIF-Induced Expression of c-Met and CXCR4 and Reduces Primary Tumor Growth and Metastasis of Uveal Melanoma.
Dong L; You S; Zhang Q; Osuka S; Devi NS; Kaluz S; Ferguson JH; Yang H; Chen G; Wang B; Grossniklaus HE; Van Meir EG
Clin Cancer Res; 2019 Apr; 25(7):2206-2218. PubMed ID: 30563937
[TBL] [Abstract][Full Text] [Related]
28. EFS shows biallelic methylation in uveal melanoma with poor prognosis as well as tissue-specific methylation.
Neumann LC; Weinhäusel A; Thomas S; Horsthemke B; Lohmann DR; Zeschnigk M
BMC Cancer; 2011 Aug; 11():380. PubMed ID: 21871071
[TBL] [Abstract][Full Text] [Related]
29. Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: an immunohistochemical study.
Mallikarjuna K; Pushparaj V; Biswas J; Krishnakumar S
Curr Eye Res; 2007 Mar; 32(3):281-90. PubMed ID: 17453948
[TBL] [Abstract][Full Text] [Related]
30. SLC25A38 as a novel biomarker for metastasis and clinical outcome in uveal melanoma.
Fan Z; Duan J; Luo P; Shao L; Chen Q; Tan X; Zhang L; Xu X
Cell Death Dis; 2022 Apr; 13(4):330. PubMed ID: 35411037
[TBL] [Abstract][Full Text] [Related]
31. Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications.
Economou MA; All-Ericsson C; Bykov V; Girnita L; Bartolazzi A; Larsson O; Seregard S
Invest Ophthalmol Vis Sci; 2005 Dec; 46(12):4372-5. PubMed ID: 16303922
[TBL] [Abstract][Full Text] [Related]
32. Dual Targeting of CDK4/6 and cMET in Metastatic Uveal Melanoma.
Ohara M; Saito K; Kageyama K; Terai M; Cheng H; Aplin AE; Sato T
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33806615
[TBL] [Abstract][Full Text] [Related]
33. Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration.
Chattopadhyay C; Grimm EA; Woodman SE
PLoS One; 2014; 9(2):e83957. PubMed ID: 24551032
[TBL] [Abstract][Full Text] [Related]
34. ADAM10 correlates with uveal melanoma metastasis and promotes in vitro invasion.
Gangemi R; Amaro A; Gino A; Barisione G; Fabbi M; Pfeffer U; Brizzolara A; Queirolo P; Salvi S; Boccardo S; Gualco M; Spagnolo F; Jager MJ; Mosci C; Rossello A; Ferrini S
Pigment Cell Melanoma Res; 2014 Nov; 27(6):1138-48. PubMed ID: 25124714
[TBL] [Abstract][Full Text] [Related]
35. Stimulation and inhibition of uveal melanoma invasion by HGF, GRO, IL-1alpha and TGF-beta.
Woodward JK; Elshaw SR; Murray AK; Nichols CE; Cross N; Laws D; Rennie IG; Sisley K
Invest Ophthalmol Vis Sci; 2002 Oct; 43(10):3144-52. PubMed ID: 12356817
[TBL] [Abstract][Full Text] [Related]
36. IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression.
Lapadula D; Lam B; Terai M; Sugase T; Tanaka R; Farias E; Kadamb R; Lopez-Anton M; Heine CC; Modasia B; Aguirre-Ghiso JA; Aplin AE; Sato T; Benovic JL
Mol Cancer Ther; 2023 Jan; 22(1):63-74. PubMed ID: 36223548
[TBL] [Abstract][Full Text] [Related]
37. YAP/TAZ Activation Drives Uveal Melanoma Initiation and Progression.
Li H; Li Q; Dang K; Ma S; Cotton JL; Yang S; Zhu LJ; Deng AC; Ip YT; Johnson RL; Wu X; Punzo C; Mao J
Cell Rep; 2019 Dec; 29(10):3200-3211.e4. PubMed ID: 31801083
[TBL] [Abstract][Full Text] [Related]
38. Metastatic uveal melanoma: biology and emerging treatments.
Woodman SE
Cancer J; 2012; 18(2):148-52. PubMed ID: 22453016
[TBL] [Abstract][Full Text] [Related]
39. Liver metastasis in uveal melanoma - treatment options and clinical outcome.
Kaštelan S; Mrazovac Zimak D; Ivanković M; Marković I; Gverović Antunica A
Front Biosci (Landmark Ed); 2022 Feb; 27(2):72. PubMed ID: 35227015
[TBL] [Abstract][Full Text] [Related]
40. Uveal melanoma modeling in mice and zebrafish.
van den Bosch QCC; de Klein A; Verdijk RM; Kiliç E; Brosens E;
Biochim Biophys Acta Rev Cancer; 2024 Jan; 1879(1):189055. PubMed ID: 38104908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
